Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improving Prognostic Modeling in Myelodysplastic Syndromes.

Current hematologic malignancy reports - 1 Dec 2016

Nazha Aziz, Sekeres Mikkael A

Abstract excerpt

Myelodysplastic syndromes (MDSs) are a heterogeneous group of disorders characterized by the accumulation of complex genetic alterations that drive disease pathogenesis and outcome. Several prognostic models have been developed over the last two decades to risk stratify patients with MDS. These models mainly used clinical variables including blast percentage, cytopenias, cytogenetics, transfusion dependency, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytogenetics
Share to DNA Methylation
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to RNA Splicing

Share to Transcription Factors

Source

Identifiers

PMID: 27502092
DOI: 10.1007/s11899-016-0342-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improving Prognostic Modeling in Myelodysplastic Syndromes.PMID 27502092Read ↗

Prognostic models in myelodysplastic syndromes.Semantic proximity Read ↗

Novel Prognostic Models for Myelodysplastic Syndromes.Semantic proximity Read ↗

Current state of prognostication and risk stratification in myelodysplastic syndromes.Semantic proximity Read ↗

Clinical and genetic predictors of prognosis in myelodysplastic syndromesSemantic proximity Read ↗

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes.Semantic proximity Read ↗

MDS prognostic scoring systems – past, present, and future.Semantic proximity Read ↗

The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.Semantic proximity Read ↗

Updates in Risk Stratification in Myelodysplastic Syndromes.Semantic proximity Read ↗

[Molecular international prognostic scoring system for myelodysplastic syndromes].Semantic proximity Read ↗

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.Semantic proximity Read ↗

When to use which molecular prognostic scoring system in the management of patients with MDS?Semantic proximity Read ↗

There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.